Take just two minutes to fill out this form and tell the FDA that they should not place tirzepatide and semaglutide on the Demonstrable Difficult to Compound list, as nominated. If these products are placed on the DDC list, pharmacists will not be allowed to compound them.
We encourage you to ask your patients to participate as well. You can fill out the form here.
NCPA
